Cargando…

Elagolix in the treatment of endometriosis: impact beyond pain symptoms

While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-rele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Archer, David F., Soliman, Ahmed M., Agarwal, Sanjay K., Taylor, Hugh S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708701/ https://www.ncbi.nlm.nih.gov/pubmed/33294846 http://dx.doi.org/10.1177/2633494120964517

Ejemplares similares

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
por: Surrey, Eric S, et al.
Publicado: (2020)

Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020)

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017)

Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials
por: Surrey, Eric S., et al.
Publicado: (2019)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
por: Carr, Bruce, et al.
Publicado: (2013)

Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
por: Abrao, Mauricio S., et al.
Publicado: (2021)

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
por: Abbas Suleiman, Ahmed, et al.
Publicado: (2020)

Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population
por: Kilpatrick, Ryan D, et al.
Publicado: (2020)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Impact of Endometriosis on Life-Course Potential: A Narrative Review
por: Missmer, Stacey A, et al.
Publicado: (2021)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Real-world characteristics of women with endometriosis-related pain entering a multidisciplinary endometriosis program
por: Agarwal, Sanjay K., et al.
Publicado: (2021)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
por: Boniface, Catherine, et al.
Publicado: (2023)

Elagolix: How far can it go in the world of gynecology?
por: Danis, Rachel B.
Publicado: (2023)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
por: Neri, Manuela, et al.
Publicado: (2019)

Changes in adenomyosis following elagolix vs leuprolide treatment in a patient with pelvic pain and infertility: A case report
por: Barseghyan, Mariam, et al.
Publicado: (2023)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2021)

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids
por: Stewart, Elizabeth A., et al.
Publicado: (2022)

Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study
por: Hunsche, Elke, et al.
Publicado: (2023)

Impact of Medical and Surgical Treatment of Endometriosis on the Cure of Endometriosis and Pain
por: Mettler, Liselotte, et al.
Publicado: (2014)

The Impact of Endometriosis on the Health of Women
por: Hughes, Claude L., et al.
Publicado: (2015)

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Current endometriosis care and opportunities for improvement
por: Pickett, Charlotte, et al.
Publicado: (2023)

Is acupuncture effective in the treatment of pain in endometriosis?
por: Lund, Iréne, et al.
Publicado: (2016)

Patient-completed or symptom-based screening tools for endometriosis: a scoping review
por: Surrey, Eric, et al.
Publicado: (2017)

Macrophage depletion: a potential immunomodulator treatment of endometriosis-associated pain?
por: D’Hooghe, Thomas M., et al.
Publicado: (2020)

Does timing matter when initiating elagolix in a natural menstrual cycle?
por: Danis, Rachel B., et al.
Publicado: (2021)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Greenness assessment of micellar spectrofluorometric approach for determination of Elagolix: application to dosage form, content uniformity and human plasma
por: Ahmed, Rasha M.
Publicado: (2021)

Endometriosis, an Ongoing Pain—Step-by-Step Treatment
por: Mechsner, Sylvia
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_93denajrucmiusmnh0286mqo7g